U.S. Antitrust Investigation of Generics to Look into Two Dozen Drugs - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - November 3, 2016 2:23 PM EDT)
U.S. prosecutors are "bearing down" on generic pharma companies in a sweeping criminal investigation into suspected price collusion, according to Bloomberg. The antitrust investigation by the DOJ spans more than a dozen companies and two dozen drugs, sources told the news service. A grand jury probe is examining some executives and the first charges could emerge by the end of the year.
Companies mentioned in the report include Mylan (NASDAQ: MYL), Allergan (NYSE: AGN) and Teva Pharma (NYSE: TEVA), Lannett (NYSE: LCI), Impax Laboratories (NASDAQ: IPXL), Covis, Sun Pharma, Mayne, Endo (NASDAQ: ENDP), and Taro Pharma (NYSE: TARO).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cellectar Biosciences (CLRB) Announces US Patent Granted for CLR 131 and CLR 125
- Chemical Financial (CHFC) Names Jeffrey Tate to Board of Directors
- Stonemor Partners (STON) Announces Resignation of CFO Sean McGrath
Create E-mail Alert Related CategoriesCorporate News, ETFs, Hot Corp. News, Litigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!